In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate

BMC Pharmacology

Volumn 2, Issue , 2002, Pages

  Carrió, Jaume ^a   Portús, Montserrat ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DOG; DOSE RESPONSE; DRUG RESISTANCE; DRUG SENSITIVITY; EXPERIMENTAL MODEL; HAMSTER; HOST; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA INFANTUM; LEISHMANIASIS; NONHUMAN; PARASITE ISOLATION; STATISTICAL SIGNIFICANCE;

EID: 0344662271     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-2-11     Document Type: Article

References (19)

1. Desjeux P: Leishmaniasis: Public health aspects and control. Clin Dermatol 1996, 14:417-423
2. Desjeux P: The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001, 95:239-243
3. Gramiccia M, Gradoni L, Orsini S: Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 1992, 86:613-620
4. Oliva G, Gradoni L, Ciaramella P, De Luna R, Cortese L, Orsini S, Davidson RN, Persechino A: Activity of liposomal amphotericin B (Ambisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995, 36:1013-1019
5. Vexenat JA, Olliaro PL, Fonseca de Castro JA, Cavalcante R, Furtado Campos JH, Tavares JP, Miles MA: Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin). Am J Trop Med Hyg 1998, 58:448-453
6. Koutinas AF, Saridomichelakis MN, Mylonakis ME, Leontides L, Polizopoulou Z, Billinis C, Argyriadis D, Diakou N, Papadopoulos O: A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet Parasitol 2001, 98:247-261
7. Grogl M, Thomason TN, Franke ED: Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992, 47:117-126
8. Jackson JE, Tally JD, Ellis WY, Mebrahtu YB, Lawyer PG, Were JB, Reed SG, Panisko DM, Limmer BL: Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg 1990, 43:464-480
9. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, Faugère B, Dumon H: In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997, 41:827-830
10. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D: Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999, 180:564-567
11. Carrió J, Riera C, Gállego M, Portús M: In vitro activity of pentavalent antimony derivatives on promastigotes and intracellular amastigotes of Leishmania infantum strains from humans and dogs in Spain. Acta Trop 2001, 79:179-183
12. Grogl M, Oduola AMJ, Cordero LDC, Kyle DE: Leishmania spp.: Development of Pentostam-resistant clones in vitro by discontinuous drug exposure. Exp Parasitol 1989, 69:78-90
13. Carrió J, Riera C, Gállego M, Ribera E, Portús M: In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients. J Antimicrob Chemother 2001, 47:120-121
14. Garin YJF, Sulahian A, Pratlong F, Méneceur P, Gangneux JP, Prina E, Dedet JP, Derouin F: Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections. Infect Immun 2001, 69:7365-7373
15. Fisa R, Gállego M, Castillejo S, Aisa MJ, Serra T, Riera C, Carrió J, Gállego J, Portús M: Epidemiology of canine leishmaniosis in Catalonia (Spain) the example of the Priorat focus. Vet Parasitol 1999, 83:87-97
16. Riera C, Valladares JE, Gállego M, Aisa MJ, Castillejo S, Fisa R, Ribas N, Carrió J, Alberola J, Arboix M: Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 1999, 84:33-47
17. Valladares JE, Riera C, Alberola J, Gállego M, Portús M, Cristòfol C, Franquelo C, Arboix M: Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet Parasitol 1998, 75:33-40
18. Valladares JE, Riera C, González-Ensenyat P, Díez-Cascón A, Ramos G, Solano-Gallego L, Gállego M, Portús M, Arboix M, Alberola J: Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation. Vet Parasitol 2001, 97:15-21
19. Carrió J, de Colmenares M, Riera C, Gállego M, Arboix M, Portús M: Leishmania infantum: Stage-specific activity of pentavalent antimony related with the assay conditions. Exp Parasitol 2000, 95:209-214